Inventiva(US:IVA)2026-01-15 18:02Summary of Inventiva's Presentation at JPMorgan Healthcare Conference Company Overview - Company: Inventiva - CEO: Andrew Openshin - Lead Asset: Lanifibranor, an oral therapy for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) - Recent Transformation: The company has undergone significant changes in the last 18 months, including a fully enrolled phase three trial and substantial funding [2][3] Financial Highlights - Funding: - $411 million raised in October 2024 - Additional $172 million raised in October [3] - Cash Balance: Expected to last until Q3 2027, assuming positive data from trials [21] Clinical Development - Phase 3 Trial: - Fully recruited with over 1,000 patients enrolled - Anticipated readout in the second half of the year - Focus on F2 and F3 patient populations, excluding F1 patients [3][17] - Phase 2b Results: - 18% effect size on fibrosis and 24% on MASH resolution - Significant improvements in cardiometabolic markers [11][12] Market Opportunity - MASH Market Size: Expected to grow to $15 billion by 2035 - Current Diagnosis Rate: Approximately 2 million diagnosed MASH patients in the U.S., representing a 25% increase since 2024 [5][6] - Target Patient Population: F2 and F3 patients, approximately 375,000 in the U.S. [6] Competitive Landscape - Treatment Evolution: - GLP-1 therapies are expected to be the backbone for F1, F2, and F3 patients - Lanifibranor positioned as a complementary oral therapy [7][8] - Safety Profile: - Low rates of peripheral edema (2%) and milder weight gain compared to previous PPAR agonists [15][16] Future Plans - Outcomes Trial: Planned for patients with compensated cirrhosis MASH to confirm clinical benefits [18] - Market Launch: Anticipated for 2028, with strategic preparations ongoing for commercialization in 2026 [20][21] Management and Strategy - Management Team: Strengthened with experienced professionals from Intercept and Ipsen [4] - Strategic Preparation: Focus on market research and building medical affairs presence in 2026 [24] Additional Insights - Patient Impact: Emphasis on the potential to reverse stages of fibrosis and improve patient outcomes [22] - Company Positioning: Plans to remain France-based while expanding U.S. commercial infrastructure [23] This summary encapsulates the key points from Inventiva's presentation, highlighting the company's strategic direction, clinical developments, market opportunities, and future plans.